Anti-methicillin resistant Staphylococcus aureus activity, synergism with oxacillin and molecular docking studies of metronidazole-triazole hybrids

European Journal of Medicinal Chemistry

Volumn 115, Issue , 2016, Pages 426e-437

  Negi, Beena ^a   Kumar, Deepak ^a   Kumbukgolla, Widuranga ^b   Jayaweera, Sampath ^b   Ponnan, Prija ^a   Singh, Ramandeep ^c   Agarwal, Sakshi ^c   Rawat, Diwan S ^a  

^a UNIVERSITY OF DELHI   (India)

^b UNIVERSITY OF COLOMBO   (Sri Lanka)

^c Vaccine and Infectious Disease Research Centre   (India)

Author keywords

Methicillin; Metronidazole; MRSA; Oxacillin; PBP2a; Triazole

Indexed keywords

1 [1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,3 TRIAZOL 4 YL]CYCLOHEXANOL; 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL) 4 [(TETRAHYDRO 2H PYRAN 2 YLOXY)METHYL] 1H 1,2,3 TRIAZOLE; 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 4 (TRIMETHYLSILYL) 1H 1,2,3 TRIAZOLE; 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 4 PROPYL 1H 1,2,3 TRIAZOLE; 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 4 [(2,4,6 TRI TERT BUTYLPHENOXY)METHYL] 1H 1,2,3 TRIAZOLE; 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 4 [(NAPHTHALEN 1 YLOXY)METHYL] 1H 1,2,3 TRIAZOLE; 1 [2 (2 METHYL 5 NITRO IMIDAZOL 1 YL)ETHYL] 4 (4 NITROPHENOXYMETHYL) 1H [1,2,3]TRIAZOLE; 1 [2 (2 METHYL 5 NITRO IMIDAZOL 1 YL)ETHYL] 4 OTOLYLOXYMETHYL 1H [1,2,3]TRIAZOLE; 1 [2 (2 METHYL 5 NITRO IMIDAZOL 1 YL)ETHYL] 4 PHENOXYMETHYL 1H [1,2,3]TRIAZOLE; 1 [2 (2 METHYL 5 NITRO IMIDAZOL 1 YL)ETHYL] 4 PHENYL 1H [1,2,3]TRIAZOLE; 1 [2 (2 METHYL 5 NITRO IMIDAZOL 1 YL)ETHYL] 4 PTOLYLOXYMETHYL 1H [1,2,3]TRIAZOLE; 1,2,3 TRIAZOLE DERIVATIVE; 2 FLUORO N [[1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,3 TRIAZOL 4 YL]METHYL]ANILINE; 2 METHYL N [[1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,3 TRIAZOL 4 YL]METHYL]ANILINE; 2 [1 [2 (2 METHYL 5 NITRO IMIDAZOL 1 YL)ETHYL] 1H [1,2,3]TRIAZOL 4 YLMETHOXY]BENZALDEHYDE; 4 (2 CHLORO PHENOXYMETHYL) 1 [2 (2 METHYL 5 NITROIMIDAZOL 1 YL)ETHYL] 1H [1,2,3]TRIAZOLE; 4 (BENZYLOXYMETHYL) 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,3 TRIAZOLE; 4 BROMOMETHYL 1 [2 (2 METHYL 5 NITRO IMIDAZOL 1 YL)ETHYL] 1H [1,2,3]TRIAZOLE; 4 [(2,3 DIMETHYLPHENOXY)METHYL] 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,3 TRIAZOLE; 4 [(2,4 DICHLOROPHENOXY)METHYL] 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,3 TRIAZOLE; 4 [(2,6 DICHLOROPHENOXY)METHYL] 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,3 TRIAZOLE; 4 [(4 ISO PROPYLPHENOXY)METHYL] 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,3 TRIAZOLE; 4 [(4 TERT BUTYLPHENOXY)METHYL] 1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,3 TRIAZOLE; 4 [1 [2 (2 METHYL 5 NITRO IMIDAZOL 1 YL)ETHYL] 1H [1,2,3]TRIAZOL 4 YLMETHOXY]BENZALDEHYDE; ANTIBIOTIC AGENT; METRONIDAZOLE; N [[1 [2 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,3 TRIAZOL 4 YL]METHYL]ANILINE; OXACILLIN; PROPIONICACID 1 [2 (2 METHYL 5 NITRO IMIDAZOL 1 YL)ETHYL] 1H [1,2,3]TRIAZOL 4 YLMETHYL ESTER; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIINFECTIVE AGENT; TRIAZOLE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; CLICK CHEMISTRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SYNTHESIS; HYDROGEN BOND; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; NONHUMAN; BACTERIAL COUNT; DRUG EFFECTS;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG SYNERGISM; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; METRONIDAZOLE; TRIAZOLES;

EID: 84962361083     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.03.041     Document Type: Article

References (44)

1. M.C. Enright, D.A. Robinson, G. Randle, E.J. Feil, H. Grundmann, B.G. Spratt, The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA), Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7687-7692.
2. S.Y.C. Tong, L. Varrone, M.D. Chatfield, M. Beaman, P.M. Giffard, Progressive increase in community-associated methicillin resistant Staphylococcus aureus in Indigenous populations in northern Australia from 1993 to 2012, Epidemiol. Infect. 143 (2015) 1519-1523.
3. A. Waness, Revisiting methicillin-resistant Staphylococcus aureus infections, J. Glob. Infect. Dis. 2 (2010) 49-56.
4. G.L. Archer, Staphylococcus aureus: a well-armed pathogen, Clin. Infect. Dis. 26 (1998) 1179-1181.
5. M.Z. David, R.S. Daum, Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic, Clin. Microbiol. Rev. 23 (2010) 616-687.
6. B.W. Frazee, J. Lynn, E.D. Charlebois, L. Lambert, D. Lowery, F. Perdreau-Remington, High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections, Ann. Emerg. Med. 45 (2005) 311-320.
7. E. Klein, D.L. Smith, R. Laxminarayan, Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005, Emerg. Infect. Dis. 13 (2007) 1840-1846.
8. A.P. Fraise, Tigecycline: the answer to beta-lactam and fluoroquinolone resistance? J. Infect. 53 (2006) 293-300.
9. I.A. Critchley, R.S. Blosser-Middleton, M.E. Jones, C. Thornsberry, D.F. Sahm, J.A. Karlowsky, Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001, Antimicrob. Agents Chemother. 47 (2003) 1689-1693.
10. R. Bouley, M. Kumarasiri, Z. Peng, L.H. Otero, W. Song, M.A. Suckow, V.A. Schroeder, W.R. Wolter, E. Lastochkin, N.T. Antunes, H. Pi, S. Vakulenko, J.A. Hermoso, M. Chang, S. Mobashery, Discovery of antibiotic (E)-3-(3-carboxyphenyl)-2-(4-cyanostyryl)quinazolin-4(3H)-one, J. Am. Chem. Soc. 137 (2015) 1738-1741.
11. C. Walsh, G. Wright, Introduction: antibiotic resistance, Chem. Rev. 105 (2005) 391-394.
12. R. Fernandez, L.I. Paz, R.R. Rosato, A.E. Rosato, Ceftaroline is active against hetero resistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance, Antimicrob. Agents Chemother. 58 (2014) 5736-5746.
13. K. Hiramatsu, Y. Katayama, M. Matsuo, T. Sasaki, Y. Morimoto, A. Sekiguchi, T. Baba, Multi-drug-resistant Staphylococcus aureus and future chemotherapy, J. Infect. Chemother. 20 (2014) 593-601.
14. K.K. Kumarasamy, M.A. Toleman, T.R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, U. Chaudhary, M. Doumith, C.G. Giske, S. Irfan, P. Krishnan, A.V. Kumar, S. Maharjan, S. Mushtaq, T. Noorie, D.L. Paterson, A. Pearson, C. Perry, R. Pike, B. Rao, U. Ray, J.B. Sarma, M. Sharma, E. Sheridan, M.A. Thirunarayan, J. Turton, S. Upadhyay, M. Warner, W. Welfare, D.M. Livermore, N. Woodford, Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study, Lancet Infect. Dis. 10 (2010) 597-602.
15. K. Bush, P. Courvalin, G. Dantas, J. Davies, B. Eisenstein, P. Huovinen, G.A. Jacoby, R. Kishony, B.N. Kreiswirth, E. Kutter, S.A. Lerner, S. Levy, K. Lewis, O. Lomovskaya, J.H. Miller, S. Mobashery, L.J. Piddock, S. Projan, C.M. Thomas, A. Tomasz, P.M. Tulkens, T.R. Walsh, J.D. Watson, J. Witkowski, W. Witte, G. Wright, P. Yeh, H.I. Zgurskaya, Tackling antibiotic resistance, Nat. Rev. Microbiol. 9 (2011) 894-896.
16. C.A. Arias, B.E. Murray, Antibiotic-resistant bugs in the 21st centuryea clinical super-challenge, New Engl. J. Med. 360 (2009) 439-443.
17. M. Matsuhashi, M.D. Song, F. Ishino, M. Wachi, M. Doi, M. Inoue, K. Ubukata, N. Yamashita, M. Konno, Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to β-lactam antibiotics in Staphylococcus aureus, J. Bacteriol. 167 (1986) 975-980.
18. T. Ito, Y. Katayama, K. Hiramatsu, Cloning and nucleotide sequence determination of the entire mecA DNA of pre-methicillin-resistant Staphylococcus aureus N315, Antimicrob. Agents Chemother. 43 (1999) 1449-1458.
19. A.L. Lovering, M.C. Gretes, S.S. Safadi, F. Danel, L. de Castro, M.G.P. Page, N.C.J. Strynadka, Structural insights into the anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole, J. Biolog. Chem. 287 (2012) 32096-32102.
20. L.H. Otero, A. Rojas-Altuve, L.I. Llarrull, C. Carrasco-López, M. Kumarasiri, E. Lastochkin, J. Fishovitz, M. Dawley, D. Hesek, M. Lee, J.W. Johnson, J.F. Fisher, M. Chang, S. Mobashery, J.A. Hermoso, How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function, Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 16808-16813.
21. J. Fishovitz, A. Rojas-Altuve, L.H. Otero, M. Dawley, C. Carrasco-Lopez, M. Chang, J.A. Hermoso, S. Mobashery, Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics, J. Am. Chem. Soc. 136 (2014) 9814-9817.
22. I. Acebrón, M. Chang, S. Mobashery, J.A. Hermoso, The allosteric site for the nascent cell wall in penicillin-binding protein 2a: an Achilles' Heel of methicillin-resistant Staphylococcus aureus, Curr. Med. Chem. 22 (2015) 1678-1686.
23. S. Lofmark, C. Edlund, C.E. Nord, Metronidazole is still the drug of choice for treatment of anaerobic infections, Clin. Infect. Dis. 50 (2010) S16-S23.
24. S.F. Cui, L.P. Peng, H.Z. Zhang, S. Rasheed, K.V. Kumar, C.H. Zhou, Novel hybrids of metronidazole and quinolones: synthesis, bioactive evaluation, cytotoxicity, preliminary antimicrobial mechanism and effect of metal ions on their transportation by human serum albumin, Eur. J. Med. Chem. 86 (2014) 318-334.
25. Y.T. Duan, Z.C. Wang, Y.L. Sang, X.X. Tao, S.B. Teraiya, P.F. Wang, Q. Wen, X.J. Zhou, L. Ding, Y.H. Yang, H.L. Zhu, Design and synthesis of 2-styryl of 5-nitroimidazole derivatives and antimicrobial activities as FabH inhibitors, Eur. J. Med. Chem. 76 (2014) 387-396.
26. S.F. Wang, Y. Yin, F. Qiao, X. Wu, S. Sha, L. Zhang, H.L. Zhu, Synthesis, molecular docking and biological evaluation of metronidazole derivatives containing piperazine skeleton as potential antibacterial agents, Bioorg. Med. Chem. 22 (2014) 2409-2415.
27. W. Hu, R.W. Burli, J.A. Kaizerman, K.W. Johnson, M.I. Gross, M. Iwamoto, P. Jones, D. Lofland, S. Difuntorum, H. Chen, B. Bozdogan, P.C. Appelbaum, H.E. Moser, DNA binding ligands with improved in vitro and in vivo potency against drug-resistant Staphylococcus aureus, J. Med. Chem. 47 (2004) 4352-4355.
28. X.L. Hu, D. Li, L. Shao, X. Dong, X.P. He, G.R. Chen, D. Chen, Triazole-linked glycolipids enhance the susceptibility of MRSA to β-lactam antibiotics, ACS Med. Chem. Lett. 6 (2015) 793-797.
29. Beena, N. Kumar, R.K. Rohilla, N. Roy, D.S. Rawat, Synthesis and antibacterial activity evaluation of metronidazole-triazole conjugates, Bioorg. Med. Chem. Lett. 19 (2009) 1396-1398.
30. B. Negi, K.K. Raj, S.M. Siddiqui, D. Ramachandran, A. Azam, D.S. Rawat, In vitro antiamoebic activity evaluation and docking studies of metronidazoleetriazole hybrids, Chem. Med. Chem. 11 (2014) 2439-2444.
31. Beena, D. Kumar, M.A. Bailey, T. Parish, D.S. Rawat, Synthesis and antituberculosis activity evaluation of cyclohexane-1,2-diamine derivatives, Chem. Biol. Interface. 4 (2014) 1-14.
32. Beena, D. Kumar, W. Kumbukgolla, S. Jayaweera, M.A. Bailey, T. Alling, J. Ollinger, T. Parish, D.S. Rawat, Antibacterial activity of adamantyl substituted cyclohexane diamine derivatives against methicillin resistant Staphylococcus aureus and Mycobacterium tuberculosis, RSC Adv. 4 (2014) 11962-11966.
33. D. Kumar, K.K. Raj, M.A. Bailey, T. Alling, T. Parish, D.S. Rawat, Antimycobacterial activity evaluation, time-kill kinetic and 3D-QSAR study of C- (3-aminomethyl-cyclohexyl)-methylamine derivatives, Bioorg. Med. Chem. Lett. 23 (2013) 1365-1369.
34. Beena, S. Joshi, N. Kumar, S. Kidwai, R. Singh, D.S. Rawat, Synthesis and antitubercular activity evaluation of novel unsymmetrical cyclohexane-1,2-diamine derivatives, Arch. Pharm. Chem. Life Sci. 345 (2012) 896-901.
35. D. Kumar, Beena, G. Khare, A.K. Tyagi, R. Singh, D.S. Rawat, Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro antimycobacterial activity evaluation, Eur. J. Med. Chem. 81 (2014) 301-313.
36. R.C. Knight, I.M. Skolimowski, D.I. Edwards, The interaction of reduced metronidazole with DNA, Biochem. Pharmacol. 27 (1978) 2089-2093.
37. J.H. Tocher, D.I. Edwards, Evidence for the direct interaction of reduced metronidazole derivatives with DNA bases, Biochem. Pharmacol. 48 (1994) 1089-1094.
38. N. Pick, S. Cameron, D. Arad, Y. Av-Gay, Screening of compounds toxicity against human monocytic cell line-THP-1 by flow cytometry, Biol. Proced. Online 6 (2004) 220-225.
39. I. Garcia, C. Pouzet, M. Brulas, E. Bauza, J.M. Botto, N. Domloge, Evaluation of THP-1 cell line as an in vitro model for long-term safety assessment of new molecules, Int. J. Cosmet. Sci. 35 (2013) 568-574.
40. D. Lim, N.C. Strynadka, Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus, Nat. Struct. Biol. 9 (2002) 870-876.
41. Qik Prop User Manual Copyright ©, Schrödinger, LLC, 2013.
42. J.J. Lu, K. Crimin, J.T. Goodwin, P. Crivori, C. Orrenius, L. Xing, P.J. Tandler, T.J. Vidmar, B.M. Amore, A.G.E. Wilson, P.F.W. Stouten, P.S. Burton, Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat, J. Med. Chem. 47 (2004) 6104-6107.
43. P. Artursson, K. Palm, K. Luthman, Caco-2 monolayers in experimental and theoretical predictions of drug transport, Adv. Drug. Deliv. Rev. 46 (2001) 27-43.
44. Glide 5.8 User Manual Copyright ©, Schrödinger, LLC, 2013.